NASDAQ: ALLRAllarity Therapeutics Inc Stock
$1.55+0.06 (+4.03%)
Updated Jun 11, 2026
ALLR Price
$1.55
Fair Value Price
$1.20
Market Cap
$24.66M
52 Week Low
$0.77
52 Week High
$2.35
P/E
-2.15x
P/B
3.56x
P/S
50.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$345.00k
Earnings
-$11.25M
Gross Margin
100%
Operating Margin
-3,157.1%
Profit Margin
-3,260.6%
Debt to Equity
4.05
Operating Cash Flow
-$17M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALLR Overview
Allarity Therapeutics is a biopharma company developing oncology products and drugs for the personalized treatment of cancer. The company uses Drug Response Predictor (DRP®) technology to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures. Its pipeline products include Dovitinib, Stenoparib, Ixempra, and other formulations. Allarity was incorporated in 2004 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALLR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALLR
Ranked#188 of 463
Ranked#188 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important ALLR news, forecast changes, insider trades & much more!
ALLR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALLR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALLR ($1.55) is overvalued by 29.27% relative to our estimate of its Fair Value price of $1.20 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALLR ($1.55) is not significantly undervalued (29.27%) relative to our estimate of its Fair Value price of $1.20 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALLR due diligence checks available for Premium users.
Valuation
ALLR fair value
Fair Value of ALLR stock based on Discounted Cash Flow (DCF)
Price
$1.55
Fair Value
$1.20
Overvalued by
29.27%
ALLR ($1.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALLR ($1.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALLR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALLR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.15x
Industry
17.66x
Market
13.95x
ALLR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.56x
Industry
4.83x
ALLR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALLR's financial health
Profit margin
Revenue
$25.0k
Net Income
-$2.8M
Profit Margin
-11,000%
ALLR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALLR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$34.9M
Liabilities
$28.0M
Debt to equity
4.05
ALLR's short-term assets ($34.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALLR's short-term assets ($34.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALLR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
-$64.0k
Financing
$19.7M
ALLR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALLR vs Biotech Stocks
Allarity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.